FDA Approves Merck’s Keytruda for Endometrial Carcinoma

Merck says FDA approved Keytruda as a single agent for certain patients with advanced endometrial carcinoma.

• Approval is for treatment of patients whose carcinoma is microsatellite instability-high or mismatch repair deficient, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation
• “We have seen substantial progress in delivering treatment options for patients with advanced endometrial cancer with KEYTRUDA, as monotherapy and in combination, with two approved indications in this area,” said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories

NOTE

• Merck & ...